Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
Article

Association of Low Concentrations of Serum Mannose-Binding Protein with Recurrent Infections in Adults

Vellalore N. Kakkanaiah, Guo Qiu Shen, Emmanuel A. Ojo-Amaize, James B. Peter
Vellalore N. Kakkanaiah
Specialty Laboratories, Santa Monica, California 90404-3900
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guo Qiu Shen
Specialty Laboratories, Santa Monica, California 90404-3900
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel A. Ojo-Amaize
Specialty Laboratories, Santa Monica, California 90404-3900
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James B. Peter
Specialty Laboratories, Santa Monica, California 90404-3900
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CDLI.5.3.319-321.1998
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Low concentrations of mannose-binding protein (MBP; also known as mannose-binding lectin) are associated with common opsonic defect in immunodeficient children. We compared the concentrations of MBP in the sera of 47 adults with non-human immunodeficiency virus-related recurrent infections (group I) and 50 healthy adult controls. Mean serum MBP concentrations in the patient group did not differ significantly from those in the control group (P < 0.4). Nevertheless, the proportion of individuals with less than 5 ng of serum MBP per ml was significantly larger in the patient group (21%, P = 0.01) than in the control group (4%). Group II consisted of 73 pediatric and 56 adult patients with recurrent infections. Pediatric patients had significantly lower mean concentrations of serum MBP than their controls (P < 0.005), and there was no significant difference between the concentrations in sera of adult patients and adult controls (P < 0.4). Again, the proportion of individuals with less than 5 ng of serum MBP per ml was significantly larger in both pediatric (22%, P = 0.045) and adult (38%,P = 0.000016) patients than in their respective controls (4%). Our results demonstrate that, as in children, low concentrations of serum MBP can be associated with recurrent infections in adults.

Human mannose-binding protein (MBP) is a calcium-dependent lectin secreted by the liver as an acute-phase protein which plays an important role in innate immunity (16). By binding to mannose orN-acetylglucosamine on the surfaces of various pathogens, MBP mediates opsonization and subsequent phagocytosis (4). MBP can also associate with serine proteases (MASP-1 and MASP-2) to activate the third complement activation pathway independent of antibody or C1q (7, 14).

The low concentrations of MBP in human serum associated with a common defect in opsonization (12) are characterized by three different point mutations in one of the coding regions of the MBP gene with resultant amino acid changes in the collagen-like region of the molecule (5, 6, 10). Individuals homozygous or heterozygous for one or a combination of any of the three mutations are at risk for developing recurrent infections, not only early in life before development of their own antibody responses (12, 17) but also as older children and adults (2, 11).

Recent discoveries of an association between deficiencies in MBP and several diseases, such as systemic lupus erythematosus (1), recurrent spontaneous abortion (3), hepatitis B (15), and tuberculosis (9), implicate MBP variance as one of the genetic susceptibility factors in various infections (16). The present study was undertaken to ascertain whether there is an association between deficiencies in MBP and suspected immunodeficiency in adult patients.

MATERIALS AND METHODS

Patients.Patients’ specimens were remnants of serum samples sent to Specialty Laboratories for routine clinical testing and were from two different groups. Group I consisted of 47 adult patients (33 females, ages 29 to 86, and 14 males, ages 24 to 72) with non-human immunodeficiency virus (HIV)-related recurrent infections and a history of repeated hospitalization. Group II consisted of 73 pediatric patients (30 females and 43 males, ages <19 years) and 56 adult patients (35 females and 21 males, ages >19 years) with recurrent infections whose sera had been sent for a humoral immune response survey following pneumococcal vaccination.

Control subjects.Group III (the control group) included 23 healthy pediatric subjects and 50 healthy adult subjects. Sera from the healthy pediatric subjects (ages <19 years) were remnant samples from a previous study on Bartonella-HIV encephalopathy conducted in collaboration with Benjamin Estrada, New Orleans, La. Sera from the adult subjects were obtained from volunteers who were employed at Specialty Laboratories. All the adult serum donors were remunerated.

Purification of human MBP.Human MBP was purified from pooled human AB serum (American Qualex, San Clemente, Calif.) as described earlier (13). Briefly, 500 ml of pooled human AB serum was dialyzed extensively against loading buffer containing 20 mM Tris (pH 7.4), 0.15 M NaCl, 1.0 mM CaCl2, and 0.05% NaN3. Following dialysis, the serum was loaded on a mannan-agarose column (Sigma Chemical Co., St. Louis, Mo.) which was equilibrated with loading buffer. The loaded column was washed extensively with loading buffer, and the bound protein was eluted with a solution of 20 mM Tris (pH 7.4), 0.15 M NaCl, 0.01 M EDTA, and 0.05% NaN3. The fractions with higher absorbances (280 nm) were pooled, and the serum amyloid P component was removed by CaCl2 precipitation. Following concentration by ultrafiltration (filter from Amicon), the presence of MBPs was confirmed by Western blotting with mouse monoclonal antibodies to human MBP (Harlan Bioproducts for Science, Inc., Indianapolis, Ind.). Protein concentrations were determined with the Bio-Rad protein assay reagent with bovine serum albumin as the standard.

Generation of rabbit antibodies to human MBP.One milligram of purified human MBP was mixed with 1 ml of Titermax (Sigma Chemical Co.) and injected subcutaneously into three rabbits (Universal Animal Care, Bloomington, Calif.). Three weeks following immunization, the rabbits were bled for sera. The sera were tested for MBP-specific antibodies by Western blotting. The immunoglobulin G fraction of the MBP-specific antibodies was purified from the serum with a high titer by using a protein A-Sepharose column (13).

Assay for MBP.Serum MBP concentrations were determined by a sandwich enzyme-linked immunosorbent assay (sandwich ELISA) as described earlier (13). Briefly, Immulon 2 ELISA plates (Dynatech Laboratories, Inc., Chantilly, Va.) were coated overnight at 4°C with 100 μl of purified rabbit anti-human MBP immunoglobulin G per well at a concentration of 1 μg/ml in carbonate buffer (50 mM Na2CO3, pH 9.6). The following morning, the plates were washed three times with washing solution (phosphate-buffered saline with 0.05% Tween 20 [PBS-T]) and blocked with 1% bovine serum albumin in PBS-T for 1 h at room temperature (RT). One-hundred-microliter aliquots of serum samples or standards per well were added to the antibody-coated plates and incubated overnight at 4°C. Different concentrations of MBP were used as standards in twofold dilutions. Following incubation, the plates were washed as before and 100 μl of biotinylated anti-MBP mouse monoclonal antibody (0.5 μg/ml) was added per well. The plates were incubated at RT for 2 h. At the end of the incubation, the plates were washed, 100 μl of 1:2,000-diluted alkaline phosphatase-conjugated streptavidin (Boehringer Mannheim Corporation, Indianapolis, Ind.) was added to each well, and the plates were incubated at RT for 1 h. Following incubation, the plates were washed and 150 μl of the substrate,p-nitrophenyl phosphate (1 mg/ml) (Sigma Chemical Co.), was added to all the wells. The plates were kept in the dark for 30 min and then read in an ELISA reader. Data were analyzed by using a four-parameter standard curve (Softmax software; Molecular Devices, Sunnyvale, Calif.).

Reference range.The cutoff value of 5 ng of serum MBP per ml was chosen on the basis of the earlier report that individuals with homozygosity of abnormal MBP alleles had <10 ng of serum MBP per ml (10) and that homozygosity for MBP mutant alleles predisposes individuals to recurrent infections (2).

Statistical analysis.Student’s t test and Fisher’s exact test were employed to evaluate differences between control and patient groups.

RESULTS

MBP concentrations in adult patients with recurrent infections.The serum samples from 47 adults with non-HIV-related recurrent infections (group I) were screened for MBP concentrations by ELISA and compared with those from 50 healthy adults. The mean concentration of MBP in sera of the patient group (48.9 ± 12 ng/ml) did not differ significantly from that in sera of the control individuals (50.0 ± 7 ng/ml, P < 0.4) (Fig.1). Patients’ serum samples had a median MBP concentration of 20 ng/ml (with a range of 0 to 425 ng/ml), while the controls’ serum samples had a median MBP concentration of 38 ng/ml (with a range of 0 to 360 ng/ml). However, the number of individuals with less than 5 ng of MBP per ml in their serum was significantly larger (10 of 47 [21%], P = 0.01) than the number in the control group (2 of 50 [4%]).

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Serum MBP concentrations in adult patients with recurrent infections. MBP concentrations were determined by the enzyme immunoassay method as described in Materials and Methods. Open circles represent the mean values, and the dotted line indicates the cutoff value.

MBP concentrations in pediatric and adult patients with recurrent infections.We also measured serum MBP concentrations in 73 pediatric and 56 adult patients with recurrent infections (group II). The sera from pediatric patients had a significantly lower mean concentration of MBP (78.9 ± 13 ng/ml; median, 31 ng/ml, with a range of 0 to 199 ng/ml) than sera from controls (150.2 ± 30 ng/ml, P < 0.005; median, 122 ng/ml, with a range of 0 to 499 ng/ml) (Fig. 2). However, the mean concentration of MBP in the sera of pediatric patients was significantly higher than that in the sera of adult patients (45.2 ± 10 ng/ml, P < 0.025). In contrast, there was no significant difference between the mean serum MBP concentrations in adult patients and those in controls (50.0 ± 7 ng/ml,P < 0.4).

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Serum MBP concentrations in pediatric and adult patients with recurrent infections. Serum samples from pediatric and adult patients with suspected immunodeficiency were screened for MBP as described in Materials and Methods. Open circles represent the mean values, and the dotted line indicates the cutoff value.

Sixteen of 73 (22%, P = 0.045) pediatric immunodeficiency patients had less than 5 ng of serum MBP per ml, compared to 1 of 23 (4%) healthy children. Similarly, 21 of 56 adult immunodeficiency patients (38%, P = 0.000016) and 4% of healthy adult controls had less than 5 ng of MBP per ml of their serum.

DISCUSSION

The mean concentration of MBP in the sera of adults with non-HIV-related recurrent infections did not differ from that in the sera of healthy control individuals. In a childhood syndrome, recurrent infections, failure to thrive, and chronic diarrhea can be associated with low levels or the absence of MBP (12). Because low serum MBP concentrations can result in a common opsonic defect, MBP is thought to play a critical role during infancy, especially before the development of the antibody repertoire (12, 17). Identification of the homozygous phenotype caused by two mutations of the MBP gene (at codons 54 and 52) in an adult immunodeficiency patient suggests that MBP confers a lifelong risk of infection on both children and adults (11).

This paper is the first comprehensive report that the average concentrations of MBP in serum are similar in adult patients and healthy adult subjects. However, an absence or lower concentrations of serum MBP (less than 5 ng/ml) were present in 21% of the adults with recurrent infections. This significant increase in frequency might reflect a higher incidence of the homozygous mutations in MBP genes in adult patients (9). The proportion of patients with lower concentrations of serum MBP (<5 ng/ml) is similar to that in earlier reports regarding patients with suspected immunodeficiency (2). Further analysis of these patients by genotypic investigation for various mutations will be required to confirm these results.

Group II included both pediatric and adult patients with suspected immunodeficiency. The children had significantly higher concentrations of serum MBP than adult patients, which is in agreement with earlier reports (13). Interestingly, in contrast to adult patients, pediatric patients had a significantly lower mean concentration of serum MBP than did controls. This may be due to the possible increase in heterozygous mutations in the patients, as reported earlier (9). The serum MBP concentrations in adult patients were not significantly lower than those in control subjects, as in group I. On the other hand, the number of patients in group II with less than 5 ng of MBP per ml of serum is significantly higher than in group III. Again, this may be due to the increase in homozygous mutations in the groups of patients, as previously reported (9).

Alternatively, the increase in the proportion of patients with less than 5 ng of MBP per ml of serum may be due to the clearance of serum MBP during an infection in which it is involved. However, studies on the levels of circulating MBP during HIV infection showed a higher level of MBP in HIV-seropositive patients than in members of the control group (8). Therefore, it is possible that the absence of MBP in a significant number of our patients may not be due to the clearance of MBP during infection. Thus, our results, along with the recent discovery of MBP mutations in patients with infectious diseases, such as tuberculosis (9) and hepatitis B (15), are consistent with a lifelong increased risk of infections in some patients with low levels or an absence of serum MBP.

ACKNOWLEDGMENTS

We thank Ashu Kumar, Foaad Hanna, and Narsis Bhasharkhah for excellent technical assistance.

FOOTNOTES

    • Received 13 October 1997.
    • Returned for modification 10 December 1997.
    • Accepted 23 January 1998.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Davies E. J.,
    2. Snowden N.,
    3. Hillarby M. C.,
    4. Carthy D.,
    5. Grennan D. M.,
    6. Thomson W.,
    7. Ollier W. E. R.
    Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum. 38 1995 110 114
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Garred P.,
    2. Madsen H. O.,
    3. Hofmann B.,
    4. Svejgaard A.
    Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunedeficiency. Lancet 346 1995 941 943
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Kilpatrick D. C.,
    2. Beven B. H.,
    3. Liston W. A.
    Association between mannan binding protein deficiency and recurrent miscarriage. Hum. Reprod. 10 1995 2501 2505
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kuhlman M.,
    2. Joiner K.,
    3. Ezekowitz R. A.
    The human mannose-binding protein functions as an opsonin. J. Exp. Med. 169 1989 1733 1745
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Lipscombe R. J.,
    2. Sumiya M.,
    3. Hill A. V. S.,
    4. Lau Y. L.,
    5. Levinsky R. J.,
    6. Summerfield J. A.,
    7. Turner M. W.
    High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum. Mol. Genet. 1 1992 709 715
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Madson H. O.,
    2. Garred P.,
    3. Kurtzhals A. L.,
    4. Lamm L. U.,
    5. Ryder L. P.,
    6. Thiel S.,
    7. Svejgaard A.
    A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 40 1994 37 44
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Matsushita M.,
    2. Fujita T.
    Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J. Exp. Med. 176 1992 1497 1502
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Senaldi G.,
    2. Davies E. T.,
    3. Mahalingam M.,
    4. Lu J.,
    5. Pozniak A.,
    6. Peakman M.,
    7. Reid K. B.,
    8. Vergani D.
    Circulating levels of mannose binding protein in human immunodeficiency virus infection. J. Infect. 31 1995 145 148
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Sumiya M.,
    2. Summerfield J. A.
    Mannose-binding protein, genetic variants and the risk of infection. Q. J. Med. 89 1996 723 726
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Sumiya M.,
    2. Super M.,
    3. Tabona P.,
    4. Levinsky R. J.,
    5. Arai T.,
    6. Turner M. W.,
    7. Summerfield J. A.
    Molecular basis of opsonic defect in immunodeficient children. Lancet 337 1991 1569 1570
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Summerfield J. A.,
    2. Ryder S.,
    3. Sumiya M.,
    4. Thursz M.,
    5. Gorchein A.,
    6. Monteil M. A.,
    7. Turner M. W.
    Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 345 1995 886 889
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Super M.,
    2. Thiel S.,
    3. Lu J.,
    4. Levinsky R. J.,
    5. Turner M. W.
    Association of low levels of mannan-binding protein with a common defect in opsonisation. Lancet 2 1989 1236 1239
    OpenUrlPubMedWeb of Science
  13. 13.↵
    1. Terai I.,
    2. Kobayashi K.,
    3. Fujita T.,
    4. Hagiwara K.
    Human serum mannose binding protein (MBP): development of an enzyme-linked immunosorbent assay (ELISA) and determination of levels in serum from 1085 normal Japanese and in some body fluids. Biochem. Med. Metab. Biol. 50 1993 111 119
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Thiel S.,
    2. Vorup-Jensen T.,
    3. Stover C. M.,
    4. Schwaeble W.,
    5. Laursen S. B.,
    6. Poulsen K.,
    7. Willis A. C.,
    8. Eggleton P.,
    9. Hansen S.,
    10. Holmskov U.,
    11. Reid K. B. M.,
    12. Jensenius J. C.
    A second serine protease associated with mannan-binding lectin that activates complement. Nature 386 1997 506 510
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Thomas H. C.,
    2. Foster G. R.,
    3. Sumiya M.,
    4. McIntosh D.,
    5. Jack D. L.,
    6. Turner M. W.,
    7. Summerfield J. A.
    Mutation of gene for mannose-binding protein associated with chronic hepatitis B viral infection. Lancet 348 1996 1417 1419
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Turner M. W.
    Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol. Today 17 1996 532 540
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    Turner, M. W., M. Super, S. Singh, and R. J. Levinsky. 1991. Molecular basis of a common opsonic defect. Clin. Exp. Allergy 21(Suppl. 1):182–188.
PreviousNext
Back to top
Download PDF
Citation Tools
Association of Low Concentrations of Serum Mannose-Binding Protein with Recurrent Infections in Adults
Vellalore N. Kakkanaiah, Guo Qiu Shen, Emmanuel A. Ojo-Amaize, James B. Peter
Clinical and Diagnostic Laboratory Immunology May 1998, 5 (3) 319-321; DOI: 10.1128/CDLI.5.3.319-321.1998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Association of Low Concentrations of Serum Mannose-Binding Protein with Recurrent Infections in Adults
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Association of Low Concentrations of Serum Mannose-Binding Protein with Recurrent Infections in Adults
Vellalore N. Kakkanaiah, Guo Qiu Shen, Emmanuel A. Ojo-Amaize, James B. Peter
Clinical and Diagnostic Laboratory Immunology May 1998, 5 (3) 319-321; DOI: 10.1128/CDLI.5.3.319-321.1998
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X